Comments
GVK Biosciences today announced that it has licensed its GOSTAR toxicity and natural products database to the US Food and Drug Administration (USFDA).
The Material Transfer Agreement forms the basis of collaboration in drug repositioning, wherein the initial focus will be to identify alternative therapeutic indications of marketed compounds for neglected and orphan diseases.
GVK BIO developed a proprietary ‘Drug Repurposing Platform’ with eight different approaches to address the drug repurposing challenge. The platform will use data from GVKBIO proprietary databases like GOSTAR, biomarker database and other public databases.
GOSTAR has been developed over the span of a decade by a team comprising of more than 200 scientists. The database and application is being used globally by pharmaceutical and biotechnology companies as well as academia. It contains over 6.5 million compounds manually curated through the manual screening of over 2.5 million patents and 400,000 journals and it also contains more than 18 million quantitative SAR points.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.